The Liver-Immunity Nexus and Cancer Immunotherapy

The impact of liver metastases on immune checkpoint-inhibitor effectiveness in patients with solid-tumor malignancies has been the focus of several recent clinical and translational studies. We review the literature describing the immune functions of the liver and particularly the mechanistic observations in these studies. The initial clinical observation was that pembrolizumab appeared to be much less effective in melanoma and non-small cell lung cancer (NSCLC) patients with liver metastasis. Subsequently other clinical studies have extended and reported similar findings with programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) inhibitors in many cancers. 'Iwo recent translational studies in animal models have dissected the mechanism of this systemic immune suppression. In both studies CD11b(+) suppressive macrophages generated by liver metastasis in a two-site MC38 model appear to delete CD8(+)T cells in a FasL-dependent manner. In addition, regulatory T-cell (Treg) activation was observed and contributed to the distal immunosuppression. Finally, we discuss some of the interventions reported to address liver immune suppression, such as radiation therapy, combination checkpoint blockade, and Treg depletion.

Automated summary

Liver metastases have a significant impact on the effectiveness of immune checkpoint inhibitors in patients with solid-tumor malignancies. Multiple clinical and translational studies have shown that liver metastasis leads to systemic immune suppression through the generation of suppressive macrophages and activation of regulatory T-cells. Various interventions, such as radiation therapy and combination checkpoint blockade, have been reported to address liver immune suppression.